Download FREE Sample
Drug-device combination products are therapeutic innovations that integrate a pharmaceutical drug with a medical device to enhance treatment delivery and improve patient outcomes. These products are designed to enhance precision, enable sustained or targeted release, and provide better patient care, particularly in the management of chronic diseases such as asthma, diabetes, and cardiovascular conditions. Common examples include inhalers, insulin pens, transdermal patches, and drug-eluting stents.
The integration of drug and device technologies is fostering new possibilities in personalized medicine and digital health, with advancements like smart injectors and connected delivery systems gaining traction in research and clinical applications. Development of these products often involves multidisciplinary collaboration across pharmaceutical sciences, biomedical engineering, and clinical research, underscoring their complexity and potential to address unmet medical needs. Drug-device combination products have evolved beyond therapeutic tools and are increasingly considered platforms for personalized care and integrated disease management.
To learn more about this report, download the PDF brochure
Improving patient care: drug-device combinations for chronic disease management
The increasing global burden of chronic diseases, including diabetes, cancer, cardiovascular disorders, and respiratory disorders, continues to be a primary factor driving demand in the drug-device combination products market. These chronic conditions require long-term therapeutic management, which often requires precise, consistent, and patient-friendly therapeutic approaches, which combination products are uniquely positioned to deliver.
Drug-device combination products, such as insulin pens, drug-eluting stents, and smart inhalers, are designed to improve the accuracy of drug delivery, supporting patient adherence, and enabling convenient self-administration. These solutions are particularly beneficial for aging populations and individuals in remote or resource-limited areas, where access to regular medical care is limited.
According to the World Health Organization (WHO), noncommunicable diseases (NCDs) account for over 43 million deaths annually, making up nearly 75% of global mortality, with cardiovascular diseases leading at over 19 million deaths and diabetes causing more than 2 million deaths each year. To address this growing burden of chronic diseases, healthcare systems are increasingly adopting integrated solutions to enhance the long-term management of chronic illnesses, improve patient outcomes, and alleviate the complexities and costs associated with traditional care models.
To learn more about this report, download the PDF brochure
Patient-centricity and the aging population: key drivers for the drug device combination products market
The rising demand for minimally invasive procedures significantly boosts the growth in the drug-device combination products market. Patients and healthcare providers increasingly prefer products that deliver therapeutic benefits with less discomfort, such as wearable injectors, drug-eluting stents, and microneedle patches. These products have enabled more precise drug delivery, faster recovery, and improved patient compliance, especially for chronic conditions like diabetes, cardiovascular disease, and respiratory disorders, which often require long-term management. Additionally, the shift toward outpatient care and self-administered therapies has driven the adoption of patient-centric combination devices that reduce reliance on hospital treatment.
The increasing aging population and growing demand for precision medicine are further accelerating the adoption of drug-device combination therapies. To address this demand, manufacturers are investing in R&D to develop smart, sensor-integrated devices that combine pharmaceutical function with digital monitoring. This shift towards minimal invasive solutions is reshaping the future of combination drug-device technologies by paving the way for advanced-integrated devices that enable continuous oversight and more adaptive, patient-centric treatment regimens.
Competitive Landscape Analysis
The global drug device combination products market is marked by the presence of established and emerging market players such as Medtronic plc; Eli Lilly and Company; Stryker Corporation.; Novartis AG; Baxter International Inc.; Bayer AG; Becton, Dickinson and Company; Boston Scientific Corporation; Teleflex Incorporated; and Viatris Inc.; among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Recent developments in the drug device combination products market
The recent product launch and approvals by leading manufacturers highlight steady progress in drug-delivery technologies, thereby supporting improved clinical outcomes and the growing role of integrated treatment solutions. For instance,
- In March 2025, Terumo Europe received MDR approval for an expanded indication of its Ultimaster Nagomi and Ultimaster Tansei sirolimus-eluting coronary stent systems. This new approval covers patients at high bleeding risk, including those eligible for dual antiplatelet therapy (DAPT) for as short as one month
- In April 2023, Teikoku Seiyaku Co., Ltd. and Kowa Company, Ltd. launched ALLYDONE patches (27.5 mg and 55 mg) for managing Alzheimer's-related dementia
Report Scope
| Report Metric | Details |
| Base Year Considered | 2025 |
| Historical Data | 2024 - 2025 |
| Forecast Period | 2026 - 2031 |
| ~9% | |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Product, Application, and End-user |
| Regional Scope |
|
| Key Companies Mapped | Medtronic plc; Eli Lilly and Company; Stryker Corporation; Novartis AG; Baxter International Inc.; Bayer AG; Becton, Dickinson and Company; Boston Scientific Corporation; Teleflex Incorporated; and Viatris Inc., among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
������
Global Drug Device Combination Products Market Segmentation
This report by Medi-Tech Insights provides the������size of the global drug device combination products market at the������regional and country-level from 2024 to 2031. The report further segments the market based on product, application, and end-user.
Market Size & Forecast (2024-2031), By Product, USD Million
- Transdermal Patches
- Infusion Pumps
- Inhalers
- Drug-Eluting Stents
- Prefilled Syringes
- Drug Coated Balloons
- Others
Market Size & Forecast (2024-2031), By Application, USD Million
- Cardiovascular Disorders
- Diabetes
- Respiratory Disorders
- Oncology
- Pain Management
- Obesity
- Others
M; Forecast (2024-2031), By End-user, USD Million
- Hospitals
- Home Care Settings
- Ambulatory Surgical Centers
- Others
Market Size & Forecast (2024-2031), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Key Strategic Questions Addressed
- What is the market size & forecast of the drug device combination products market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the drug device combination products market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
Need a More Tailored Analysis?
- Discuss the market sizing methodology and forecast assumptions with our healthcare analysts.
- Expand the scope with additional countries, market segments, technologies, or competitor profiling.
- Use the insights to support strategic planning, market entry, commercial due diligence, and long-term revenue growth initiatives.
